Parravano, Mariacristina http://orcid.org/0000-0002-2223-7311
Fragiotta, Serena http://orcid.org/0000-0002-6214-6270
Costanzo, Eliana http://orcid.org/0000-0002-9916-8895
Giannini, Daniela http://orcid.org/0000-0001-5704-3931
De Geronimo, Daniele http://orcid.org/0000-0003-3242-8020
Viggiano, Pasquale http://orcid.org/0000-0002-0323-967X
Riccardo, Sacconi http://orcid.org/0000-0003-2891-2012
Querques, Giuseppe http://orcid.org/0000-0002-3292-9581
Article History
Received: 1 November 2021
Revised: 7 November 2021
Accepted: 11 November 2021
First Online: 24 November 2021
Competing interests
: The authors have no competing interests regarding the publication of this study. MP reports personal fees from Allergan, Novartis, Bayer, Zeiss, Omikron, Alfaintes, Sifi outside the submitted work. PV, EC, DG, SF, DDG has nothing to disclose. SR reported personal fees from: Novartis, Bayer, Zeiss outside the submitted work. GQ: Alimera Sciences, Inc.: Consultant/Advisor; Allegro: Advisor; Allergan: Consultant/Advisor; Apellis: Consultant/Advisor; Baush & Lomb: Consultant; Bayer Healthcare Pharmaceuticals: Consultant/Advisor; Boehringer Ingelheim: Advisor; CenterVue: Consultant/Advisor; Heidelberg Engineering: Consultant/Advisor; Lumithera: Advisor; Nevacar: Advisor; Novartis Pharmaceuticals Corporation: Consultant/Advisor; Roche: Consultant/Advisor. SIFI: Advisor/Consultant; Sooft/Fidia: Consultant; Topcon: Consultant; Thea: Consultant; Zeiss: Consultant/Advisor.